Journal of Clinical Oncology, Vol 10, 529-535, Copyright © 1992 by American Society of Clinical Oncology
Significance of epidermal growth factor receptor in advanced ovarian cancer
G Scambia, P Benedetti Panici, F Battaglia, G Ferrandina, G Baiocchi, S Greggi, R De Vincenzo and S Mancuso
Department of Gynecology and Obstetrics, Catholic University, Rome, Italy.
PURPOSE: The purpose of this study was to investigate the significance of
epidermal growth factor receptor (EGF-R) expression in a group of advanced
ovarian carcinomas. PATIENTS AND METHODS: The study was conducted on 72
previously untreated patients with International Federation of Gynecology
and Obstetrics (FIGO) stage III-IV disease. The median follow-up was 24
months (range, 4 to 75 months). EGF-R was measured by a radioreceptorial
assay. A cutoff of 1.5 fmol per milligram of protein was chosen to define
EGF-R positivity. Medians and life tables obtained with the Kaplan and
Meier method were analyzed by the log-rank test. The risk of progression
was estimated by Cox's proportional hazards model. RESULTS: EGF-R was
detected in 54% of primary tumors. When EGF-R was analyzed in different
tissue specimens of the same tumor, consistent findings were noted in 88%
(seven of eight) of cases. A lower concordance rate (nine of 15; 60%) was
found between primary tumors and omental metastases, with a tendency toward
higher EGF-R levels in the latter. The EGF-R expression did not
significantly correlate with age, stage, grading, and residual tumor after
primary surgery. In the univariate analysis, stage IV disease,
postoperative residual tumor diameter greater than 2 cm, presence of
ascites, and EGF-R positivity were found to be significantly associated
with a greater risk of disease progression. In the multivariate analysis,
only the postoperative residual tumor and the EGF-R expression remained
significantly associated with a high risk of progression. CONCLUSION: Data
reported here suggest that the presence of EGF-R in advanced ovarian tumor
at the time of the primary surgery identifies a subset of patients with a
particularly poor prognosis.
This article has been cited by other articles:
|
|
|
|
 
K. D. Cowden Dahl, J. Symowicz, Y. Ning, E. Gutierrez, D. A. Fishman, B. P. Adley, M. S. Stack, and L. G. Hudson
Matrix Metalloproteinase 9 Is a Mediator of Epidermal Growth Factor-Dependent E-Cadherin Loss in Ovarian Carcinoma Cells
Cancer Res.,
June 15, 2008;
68(12):
4606 - 4613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. D. Cowden Dahl, R. Zeineldin, and L. G. Hudson
PEA3 Is Necessary for Optimal Epidermal Growth Factor Receptor-Stimulated Matrix Metalloproteinase Expression and Invasion of Ovarian Tumor Cells
Mol. Cancer Res.,
May 1, 2007;
5(5):
413 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tanaka, S. Miyamoto, S. O. Suzuki, E. Oki, H. Yagi, K. Sonoda, A. Yamazaki, H. Mizushima, Y. Maehara, E. Mekada, et al.
Clinical Significance of Heparin-Binding Epidermal Growth Factor-Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer
Clin. Cancer Res.,
July 1, 2005;
11(13):
4783 - 4792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Miyamoto, M. Hirata, A. Yamazaki, T. Kageyama, H. Hasuwa, H. Mizushima, Y. Tanaka, H. Yagi, K. Sonoda, M. Kai, et al.
Heparin-Binding EGF-Like Growth Factor Is a Promising Target for Ovarian Cancer Therapy
Cancer Res.,
August 15, 2004;
64(16):
5720 - 5727.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Verschraegen, W. Hu, Y. Du, J. Mendoza, J. Early, M. Deavers, R. S. Freedman, R. C. Bast Jr., A. P. Kudelka, J. J. Kavanagh, et al.
Establishment and Characterization of Cancer Cell Cultures and Xenografts Derived from Primary or Metastatic Mullerian Cancers
Clin. Cancer Res.,
February 1, 2003;
9(2):
845 - 852.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Fujimura, T. Hidaka, and S. Saito
Selective Inhibition of the Epidermal Growth Factor Receptor by ZD1839 Decreases the Growth and Invasion of Ovarian Clear Cell Adenocarcinoma Cells
Clin. Cancer Res.,
July 1, 2002;
8(7):
2448 - 2454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Akimoto, N. R. Hunter, L. Buchmiller, K. Mason, K. K. Ang, and L. Milas
Inverse Relationship between Epidermal Growth Factor Receptor Expression and Radiocurability of Murine Carcinomas
Clin. Cancer Res.,
October 1, 1999;
5(10):
2884 - 2890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Baron, J. M. Lafky, C. H. Boardman, S. Balasubramaniam, V. J. Suman, K. C. Podratz, and N. J. Maihle
Serum sErbB1 and Epidermal Growth Factor Levels As Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev.,
February 1, 1999;
8(2):
129 - 137.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
B. Scoccia, Y. Mi Lee, C. Niederberger, and J. V. Ilekis
Expression of the ErbB Family of Receptors in Ovarian Cancer
Reproductive Sciences,
May 1, 1998;
5(3):
161 - 165.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E. Miyoshi, S. Higashiyama, T. Nakagawa, N. Hayashi, and N. Taniguchi
Membrane-anchored Heparin-binding Epidermal Growth Factor-like Growth Factor Acts as a Tumor Survival Factor in a Hepatoma Cell Line
J. Biol. Chem.,
May 30, 1997;
272(22):
14349 - 14355.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
